a study on Prostate Cancer
This study is being done to test an investigational drug called itraconazole in the treatment of prostate cancer.
Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse
This is a phase II, single arm study of itraconazole dosed at 300 mg PO BID in patients with noncastrate, non-metastatic, biochemically relapsed prostate cancer after prior definitive local therapy. Simon's two stage minimax design will be followed for accrual and include an interim test for lack of efficacy. There is a pre-specified stopping rule for safety after 10 patients have been treated for a minimum of 8 weeks of protocol therapy.
Prostate Cancer biochemically relapsed hormone sensitive non-metastatic after prior definitive local therapy PSA Hedgehog-signaling pathway Itraconazole Hydroxyitraconazole
Open to males ages 18 years and up
Minimum PSA: If no prior androgen deprivation therapy (ADT) for biochemical relapse:
Serum testosterone level: If no prior androgen deprivation therapy:
The two most recent measurements of serum testosterone prior to Day 1 of protocol therapy must fulfill the following criteria:
Castrate-resistant disease, as evidenced by either:
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT01787331.
© 2017 The Regents of the University of California